Germany · Delayed Price · Currency is EUR Celldex Therapeutics Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
The company is headquartered in Hampton, New Jersey.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 186 |
| CEO | Anthony Marucci |
Contact Details
Address: Perryville III Building Hampton, Delaware 08827 United States | |
| Phone | 908 200 7500 |
| Website | celldex.com |
Stock Details
| Ticker Symbol | TCE2 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anthony Marucci | Chief Executive Officer |
| Sam Martin | Chief Financial Officer |